DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the company has appointed Yadin Shemmer and Adam K. Stern to serve as board members effective immediately until t
| NEW YORK, March 5, 2020 /PRNewswire/ --DarioHealth (Formerly Known As LabStyle Innovations) Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the company has appointed Yadin Shemmer and Adam K. Stern to serve as board members effective immediately until the 2020 Annual Meeting of stock holders.
“We are very pleased to welcome Yadin and Adam to Dario’s board, and look forward to leveraging their dynamic leadership experience in digital health and extensive background in finance as we continue to develop into a leading global digital therapeutics company,” said Erez Raphael, CEO of DarioHealth. Mr. Shemmer has served in several senior operating roles across the digital health industry. From 2017 to 2019, Mr. Shemmer served as Chief Executive Officer of Mango Health, a mobile platform for medication management and patient support. Prior to Mango Health, Mr. Shemmer was President of the consumer business at Everyday Health, a provider of digital health and wellness solutions. Previously, Mr. Shemmer co-founded Better2Know, a digital diagnostic services platform in the U.K. Yadin began his career at Broadview International, a boutique investment bank serving the information technology industry. He holds an M.B.A from London Business School and a B.A from the University of Pennsylvania. “Chronic disease is a daily challenge for millions of people around the world. Addressing this challenge requires novel solutions that transform the healthcare experience for consumers and provide intelligent connectivity to payers and care teams. Dario’s solution meets this need by providing consumers with daily support while enabling care teams to monitor their populations and intervene appropriately. " said Mr. Shemmer. “I am excited to join the Board and support Dario’s mission of transforming the experience and management of chronic disease.” Mr. Stern is CEO of SternAegis Ventures and Head of Private Equity Banking at Aegis Capital Corp. He has been a venture capitalist and investment banker for more than 30 years with an emphasis on the technology and life sciences industries. Mr. Stern is a current director of Matinas Biopharma, Aerami Therapeutics, Adgero Biopharm, and Hydrofarm Holdings. Between October 2011 and May 2014, Mr. Stern served as a member of our board of directors. Prior to SternAegis Ventures, from 1997 to 2012 Mr. Stern was Senior Managing Director and Partner at Spencer Trask Ventures and from 1989 to 1997 he was Head of Private Equity Investment Banking at Josephthal & Co., Members of the New York Stock Exchange. Mr. Stern graduated with a Bachelor of Arts degree from The University of South Florida in 1987. “Dario’s technology empowers users with easy to use actionable data to improve their own health condition that provides tremendous health economic benefits to the overall healthcare system” said Adam Stern. “I’m eager to help DarioHealth become the leading SaaS healthcare solutions company in chronic care management.” About DarioHealth Corp. DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/. Cautionary Note Regarding Forward-Looking Statements This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, Dario is using forward-looking statements in this press release when it discusses Dario developing into a leading global digital therapeutics company and the leading SaaS healthcare solutions company in chronic care management y. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. DarioHealth Corporate Contact: Media Inquiries:
SOURCE DarioHealth Corp. | ||
Company Codes: NASDAQ-SMALL:DRIO, Berlin:LS1P, Munich:LS1P, Stuttgart:LS1P |
View original content:
